文献速递头痛与眩晕

Fremanezumab对慢性偏头痛患者生活质量和生产力的影响

Effect of fremanezumab on quality of life and productivity in patients with chronic migraine.
PubMed 文献 · Neurology · 2020-08-03

HALO CM试验为双盲安慰剂对照研究,将1121例慢性偏头痛患者随机分配至fremanezumab季度组、月度组或安慰剂组。结果显示,两种fremanezumab方案在MSQoL各领域、EQ-5D-5L视觉模拟量表、PGIC及WPAI:GH评分上均显著优于安慰剂。

要点

  • Fremanezumab季度或月度治疗均改善慢性偏头痛患者的生活质量。
  • 治疗还显著改善总体健康状况、患者整体变化印象和生产力。
  • 证据等级为Class II,支持fremanezumab对生活质量和生产力的获益。

核心结论

  • Fremanezumab季度或月度治疗在慢性偏头痛患者中,对偏头痛特异性生活质量、总体健康状况、患者整体变化印象及生产力的改善均优于安慰剂。

研究设计与样本

  • HALO CM为双盲、安慰剂对照试验,纳入1121例慢性偏头痛患者,按1:1:1随机分配至fremanezumab季度组(375例)、月度组(375例)或安慰剂组(371例)。

主要发现

  • 至第12周,fremanezumab季度和月度组在MSQoL各领域评分较基线的变化均显著优于安慰剂(所有p < 0.05)。
  • 第12周时,fremanezumab在EQ-5D-5L视觉模拟量表(p < 0.05)和PGIC评分(p < 0.0001)上显著改善。
  • 第12周时,fremanezumab组WPAI:GH评分(p < 0.01)和出勤主义(工作时的损害;p < 0.05)较基线的降低显著优于安慰剂。

临床怎么用

  • 对于慢性偏头痛患者,可考虑使用fremanezumab季度或月度方案以改善生活质量、总体健康状况和生产力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate fremanezumab quarterly or monthly vs placebo on health-related quality of life, health status, patients' global impression of change, and productivity in patients with chronic migraine (CM). METHODS: HALO CM was a double-blind, placebo-controlled trial in patients with CM. Patients were randomized 1:1:1 to treatment with fremanezumab quarterly (675 mg at baseline, placebo at weeks 4 and 8), fremanezumab monthly (225 mg at baseline, weeks 4 and 8), or placebo. This article assessed the effect of treatment with fremanezumab on health-related quality of life and productivity using the following prespecified assessments: the Migraine-Specific Quality of Life (MSQoL) questionnaire at baseline and weeks 4, 8, and 12; Patient Global Impression of Change (PGIC) questionnaire at weeks 4, 8, and 12; and EuroQoL 5-dimension, 5-response level (EQ-5D-5L) questionnaire and Work Productivity and Activity Impairment: General Health (WPAI:GH) questionnaire at baseline and week 12. RESULTS: The full analysis set included 1,121 patients: 375 patients with quarterly dosing, 375 with monthly dosing, and 371 with placebo. Fremanezumab quarterly and monthly was associated with significant improvements over placebo in change from baseline mean scores in MSQoL domains (all, p < 0.05) to week 12. At week 12, fremanezumab also showed significant improvements in EQ-5D-5L visual analog scale (p < 0.05) and PGIC scores (p < 0.0001) as well as significant reductions from baseline in WPAI:GH scores (p < 0.01) and presenteeism (impairment while working; p < 0.05) vs placebo. CONCLUSIONS: Fremanezumab quarterly or monthly was associated with improvement over placebo in migraine-specific quality of life, overall health status, patients' global impression of change with treatment, and productivity in patients with CM. CLINICALTRIALSGOV IDENTIFIER: NCT02621931. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that in patients with CM, treatment with fremanezumab quarterly or monthly is associated with improvements in health-related quality of life and productivity.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Lipton RB, Cohen JM, Gandhi SK, et al. Effect of fremanezumab on quality of life and productivity in patients with chronic migraine. Neurology. 2020. PMID: 32747522. doi:10.1212/WNL.0000000000010000

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。